Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.97 |
| ▸ | HTR1A | P08908 | 6/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.97 |
| ▸ | DRD1 | P21728 | 6/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.97 |
| ▸ | DRD3 | P35462 | 6/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | GFER | P55789 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylpromazine SCHEMBL18994 | 0.98 | CHRM2 (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL18993 | 0.98 | CHRM2 (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL29354434 | 0.98 | CHRM2 (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Ethopropazine SCHEMBL3690174 | 0.89 | HSD17B10 (0.80) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL2615384 | 0.88 | HTR1A (0.80) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL6944155 | 0.88 | HTR1A (0.80) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Etymemazine SCHEMBL142535 | 0.87 | CYP2D6 (0.98) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Etymemazine SCHEMBL30627534 | 0.87 | CYP2D6 (0.98) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL719590 | 0.87 | GFER (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Methylpromazine SCHEMBL21293802 | 0.87 | GFER (0.82) | CHRM2HTR1AADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400240-B1 | PERCUTANEOUSLY ABSORBABLE PATCHES | HISAMITSU PHARMACEUTICAL CO (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20040146548-A1 | Percutaneously absorbable patches | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1400240-A1 | PERCUTANEOUSLY ABSORBABLE PATCHES | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | HRH1 2332/4885CHRM2 1603/4885HTR1A 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.